Regional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis

dc.contributor.authorSolmi, Marco
dc.contributor.authorCroatto, Giovanni
dc.contributor.authorFornaro, Michele
dc.contributor.authorSchneider, Lynne Kolton
dc.contributor.authorRohani-Montez, S. Christy
dc.contributor.authorFairley, Leanne
dc.contributor.authorSmith, Nathalie
dc.contributor.authorBitter, István
dc.contributor.authorGorwood, Philip
dc.contributor.authorTaipale, Heidi
dc.contributor.authorTiihonen, Jari
dc.contributor.authorCortese, Samuele
dc.contributor.authorDragioti, Elena
dc.contributor.authorRietz, Eva Du
dc.contributor.authorNielsen, Rene Ernst
dc.contributor.authorFirth, Joseph
dc.contributor.authorFusar-Poli, Paolo
dc.contributor.authorHartman, Catharina
dc.contributor.authorHolt, Richard I.G.
dc.contributor.authorHøye, Anne
dc.contributor.authorKoyanagi, Ai
dc.contributor.authorLarsson, Henrik
dc.contributor.authorLehto, Kelli
dc.contributor.authorLindgren, Peter
dc.contributor.authorManchia, Mirko
dc.contributor.authorNordentoft, Merete
dc.contributor.authorSkonieczna-Żydecka, Karolina
dc.contributor.authorStubbs, Brendon
dc.contributor.authorVancampfort, Davy
dc.contributor.authorBoyer, Laurent
dc.contributor.authorDe Prisco, Michele
dc.contributor.authorVieta i Pascual, Eduard, 1963-
dc.contributor.authorCorrell, Christoph U.
dc.contributor.authorECNP Physical And meNtal Health Thematic Working Group (PAN-Health)
dc.date.accessioned2026-01-23T16:43:49Z
dc.date.available2026-01-23T16:43:49Z
dc.date.issued2024-02-17
dc.date.updated2026-01-23T16:43:49Z
dc.description.abstractPeople with schizophrenia die prematurely, yet regional differences are unclear. PRISMA 2020-compliant systematic review/random-effects meta-analysis of cohort studies assessing mortality relative risk (RR) versus any control group, and moderators, in people with ICD/DSM-defined schizophrenia, comparing countries and continents. We conducted subgroup, meta-regression analyses, and quality assessment. The primary outcome was all-cause mortality. Secondary outcomes were suicide-, /natural-cause- and other-cause-related mortality. We included 135 studies from Europe (n = 70), North-America (n = 29), Asia (n = 33), Oceania (n = 2), Africa (n = 1). In incident plus prevalent schizophrenia, differences across continents emerged for all-cause mortality (highest in Africa, RR=5.98, 95 %C.I.=4.09-8.74, k = 1, lowest in North-America, RR=2.14, 95 %C.I.=1.92-2.38, k = 16), suicide (highest in Oceania, RR=13.5, 95 %C.I.=10.08-18.07, k = 1, lowest in North-America, RR=4.4, 95 %C.I.=4.07-4.76, k = 6), but not for natural-cause mortality. Europe had the largest association between antipsychotics and lower all-cause mortality/suicide (Asia had the smallest or no significant association, respectively), without differences for natural-cause mortality. Higher country socio-demographic index significantly moderated larger suicide-related and smaller natural-cause-related mortality risk in incident schizophrenia, with reversed associations in prevalent schizophrenia. Antipsychotics had a larger/smaller protective association in incident/prevalent schizophrenia regarding all-cause mortality, and smaller protective association for suicide-related mortality in prevalent schizophrenia. Additional regional differences emerged in incident schizophrenia, across countries, and secondary outcomes. Significant regional differences emerged for all-cause, cause-specific and suicide-related mortality. Natural-cause death was homogeneously increased globally. Moderators differed across countries. Global initiatives are needed to improve physical health in people with schizophrenia, local studies to identify actionable moderators.
dc.format.extent83 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec746117
dc.identifier.issn0924-977X
dc.identifier.pmid38368796
dc.identifier.urihttps://hdl.handle.net/2445/226072
dc.language.isoeng
dc.publisherElsevier B.V.
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.euroneuro.2023.12.010
dc.relation.ispartofEuropean Neuropsychopharmacology, 2024, vol. 80, p. 55-69
dc.relation.urihttps://doi.org/10.1016/j.euroneuro.2023.12.010
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2024
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationEsquizofrènia
dc.subject.classificationMetaanàlisi
dc.subject.classificationMortalitat
dc.subject.otherSchizophrenia
dc.subject.otherMeta-analysis
dc.subject.otherMortality
dc.titleRegional differences in mortality risk and in attenuating or aggravating factors in schizophrenia: A systematic review and meta-analysis
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
853291.pdf
Mida:
4.32 MB
Format:
Adobe Portable Document Format